|
| Agent | Number of patients | Diagnosis | Treatment | Immune response | Clinical result |
|
| Autologous tumor cells [23] | 23 | Sarcoma | Total 1.0 × 107 cells | Delayed-type hypersensitivity (DTH) positive:
8 patients | Median survival
DTH responder: 16.6 months
Nonresponder: 8.2 months |
| Tumor translocation breakpoint specific peptide-pulsed DCs [24] | 52 | Ewing's sarcoma,
rhabdomyosarcoma | Total 4.2–143.0 × 106 cells | 39% with immune response to the translocation breakpoint,
25% with response to E7-specific | Overall survival
Vaccination: 43%
Control: 31% |
| Tumor-specific synthetic peptides or tumor lysates pulsed DCs [25] | 5 | Ewing’s sarcoma,
synovial sarcoma,
neuroblastoma | 2–15 × 106 pulsed DCs
injected 6–8 times | DTH positive:
1 patient | CR: 1 (77 months)
PD: 4 (2–27 months) |
A 9-mer peptide from
SYT-SSX fusion site [26] | 21 | Synovial sarcoma | 0.1 or 1.0 mg peptide +/− adjuvant 6 times at 14-day interval | Tetramer positive CD8:
7 patients | Stable disease (SD):
1/9 peptide alone
6/12 vaccine with adjuvant |
| Anti-CTLA-4 antibody [27] | 6 | Synovial sarcoma (expressed NY-ESO-1) | Ipilimumab 3 mg/kg
every 3 weeks for 3 cycles | DTH:
all patients negative | Time to progression
0.47–2.1 months (median 1.85),
overall survival time
0.77–19.7 months (median 8.75) |
| T cell receptor- (TCR-) transduced T cells (NY-ESO-1 specific) [28] | 6 | Synovial sarcoma (expressed NY-ESO-1) | TCR-transduced T cells
+720,000 IU/kg of IL-2 | Tetramer positive CD8:
5 patients | PR: 4
PD: 2 |
|
